Drug intelligence / Profile preview

NXL-002

Development stage: Preclinical
Lead developer: NeuExcell Therapeutics
Modality: Gene Therapies

Overview

NXL-002 is a preclinical in situ neuroregenerative gene therapy being developed by NeuExcell Therapeutics for the treatment of Huntington’s disease. It is designed to reprogram resident glial cells into functional neurons in the central nervous system, thereby replacing neurons lost to neurodegeneration rather than merely slowing disease progression. The program builds on NeuExcell’s proprietary neural regeneration platform and is part of a broader collaboration with Spark Therapeutics to apply this in situ conversion approach to central nervous system disorders, including Huntington’s disease.

Beyond the preview

Go deeper on NXL-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NXL-002.

Explore the full profile